Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.6M | $13.2M | $12.3M | $10.9M | $10.9M | $9.64M | $8.10M | $7.01M | $4.53M | $4.14M |
| Revenue growth | — | -15.1% | -6.7% | -11.4% | -0.5% | -11.3% | -15.9% | -13.5% | -35.4% | -8.5% |
| Gross profit | $3.22M | $2.47M | $1.97M | $1.48M | $1.95M | $349K | -$494K | -$281K | -$1.99M | -$132K |
| Gross margin | 20.7% | 18.7% | 16.0% | 13.6% | 18.0% | 3.6% | -6.1% | -4.0% | -43.8% | -3.2% |
| Operating income | -$8.16M | -$18.7M | -$10.4M | -$20.4M | -$2.58M | -$2.86M | -$3.55M | -$2.75M | -$4.59M | -$3.24M |
| Operating margin | -52.4% | -141.4% | -84.7% | -186.8% | -23.7% | -29.7% | -43.8% | -39.2% | -101.3% | -78.2% |
| Net income | -$9.18M | -$19.3M | -$10.8M | -$20.7M | -$2.87M | -$3.40M | -$3.97M | -$3.08M | -$4.74M | -$3.19M |
| Net margin | -59.0% | -145.9% | -87.2% | -189.5% | -26.4% | -35.3% | -49.0% | -43.9% | -104.6% | -76.9% |
| EPS (diluted) | -$0.21 | -$0.44 | -$0.25 | -$0.48 | -$0.07 | -$0.74 | -$3.78 | -$0.91 | -$2.71 | -$0.74 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.90M | $841K | $1.88M | $608K | -$42.3K | -$250K | -$410K | -$700K | -$406K | $148K |
| Capital expenditures | $193K | $136K | $51.1K | $136K | $867K | $438K | $402K | $11.5K | $38.4K | $59.3K |
| Free cash flow | $2.70M | $705K | $1.83M | $472K | -$910K | -$688K | -$812K | -$711K | -$444K | $88.9K |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.67M | $2.03M | $1.19M | $1.07M | $958K | $4.86M | $2.03M | $1.42M | $627K | $345K |
| Total assets | $78.5M | $60.0M | $45.4M | $22.2M | $21.1M | $22.6M | $17.8M | $16.5M | $14.9M | $31.0M |
| Total liabilities | $19.6M | $16.9M | $15.2M | $13.0M | $13.1M | $16.6M | $13.5M | $9.01M | $7.14M | $8.26M |
| Long-term debt | — | $9.22M | $6.54M | $4.30M | $5.24M | — | — | — | — | — |
| Shareholders' equity | $58.9M | $43.1M | $30.2M | $9.24M | $8.00M | $6.02M | $4.29M | $7.45M | $7.75M | $22.7M |
| Retained earnings | $24.8M | $5.48M | -$5.27M | -$26.0M | -$28.8M | -$32.2M | -$36.2M | -$39.3M | -$44.0M | -$47.2M |
| Shares (wtd avg diluted) | 43.6M | 43.6M | 43.6M | 43.6M | 45.6M | 4.61M | 1.05M | 3.38M | 1.75M | 4.29M |
Every figure is extracted from CHINA PHARMA HOLDINGS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.